Genmab AS (CHIX:GMABC) Moat Score: 7/10 (As of Jul. 04, 2026)


CHIX:GMABC Genmab AS CHIX:GMABC
95 GF Score
Price kr1,671.50
GF Value kr2,051.58
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Moat Score?

Genmab AS CHIX:GMABC 95 Moat Score is 7 as of Jul. 04, 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 95/100 and a GF Value™ of kr2,051.58 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,399 Biotechnology companies, Genmab AS ranks better than 99.57% on this metric.

Genmab AS has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Genmab AS has Wide Moat: Genmab AS possesses a wide moat due to its valuable intellectual property and strong R&D capabilities in biotechnology. Its innovative drug pipeline and strategic partnerships provide durable competitive advantages and significant pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Genmab AS might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Genmab AS  (CHIX:GMABc) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Genmab AS Moat Score Related Terms

CHIX:GMABC vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Genmab AS's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Moat Score distribution charts can be found below:

* The bar in red indicates where Genmab AS's Moat Score falls into.


CHIX:GMABC
95GF Score
Genmab AS CHIX:GMABC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Genmab AS (CHIX:GMABC) has a Moat Score of 7 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Genmab AS ranks #6 out of 1399 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Genmab AS's Moat Score too high?
Genmab AS's current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. Genmab AS's value of 7 is 250% above this industry median. Based on the distribution chart, Genmab AS ranks #6 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #6 out of 1399 companies for Moat Score. This places Genmab AS in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Genmab AS's value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,051.58, compared to a current price of kr1,671.50 — trading 18.5% below its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Moat Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr1,671.50 is trading 18.5% below its estimated GF Value™ of kr2,051.58. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for CHIX:GMABC:

  • Moat Score: 7
  • GF Value™: kr2,051.58 vs. price of kr1,671.50 (18.5% below fair value)
  • GF Score™: 95/100 with 5 warning signs
  • Industry Position: 250% above the Biotechnology median (#6 of 1399)

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for CHIX:GMABC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,671.50
Price
kr2,051.58
GF Value